
    
      The study is aimed to determine if oral administration of Mucinex® is effective in reducing
      the amount of corneal filaments and improving symptomology in subjects with filamentary
      keratitis. Subjects will be instructed to take 600 mg tablets of extended release Mucinex®
      twice a day (total dose is 1.2 g/day) for 4 weeks.
    
  